Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
20 déc. 2021 01h15 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Ligelizumab, a high-affinity anti-IgE antibody, demonstrated superiority compared with placebo at Week 12 in Phase III PEARL 1 and PEARL...
Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
16 déc. 2021 01h00 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Share buyback of up to USD 15bn planned to be executed by end 2023, highlighting confidence in top line growth and deep pipelineSales expected to grow...
Novartis verkauft ihre Roche-Beteiligung in einer bilateralen Transaktion an Roche
04 nov. 2021 02h00 HE
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Novartis und Roche vereinbaren bilaterale Transaktion zum Verkauf von Roche-Inhaberaktien im Besitz von Novartis zu einem Gesamtpreis von USD 20,7 Mrd. Der...
Novartis to sell its Roche stake in a bilateral transaction to Roche
04 nov. 2021 02h00 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Novartis and Roche agree a bilateral transaction for the sale of Roche bearer shares held by Novartis for a total consideration of USD 20.7 billion ...
Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an
26 oct. 2021 01h00 HE
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der wichtigsten...
Novartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz
26 oct. 2021 01h00 HE
|
Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de...
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
26 oct. 2021 01h00 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx...
Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
25 oct. 2021 01h15 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) in...
Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA
03 août 2021 01h15 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will...
Novartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées
21 juil. 2021 01h00 HE
|
Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T2 en progression de +9% (tcc1, +14% USD): Pharmaceuticals: cette unité d’affaires (UO) a vu son chiffre d’affaires progresser de...